Normalization of serum PSA level using zoledronic acid on metastatic hormone-refractory prostate cancer resistant to estramustine and betamethasone

被引：1

作者：

Seike, Kensaku ^{[1
]}

Asaeda, Yukiko ^{[2
]}

Yamamoto, Naoki ^{[3
]}

Maeda, Shinichi ^{[1
]}

机构：

[1] Toyota Mem Hosp, Dept Urol, Toyota, Japan

[2] Toyota Mem Hosp, Dept Integrated Med, Toyota, Japan

[3] Gifu Univ Hosp, Dept Urol, 1-1 Yanaido, Gifu, Gifu 5001194, Japan

来源：

CENTRAL EUROPEAN JOURNAL OF UROLOGY | 2009年 / 62卷 / 02期

关键词：

hormone-refractory prostate cancer; zoledronic acid; prostate specific antigen;

D O I：

10.5173/ceju.2009.02.art14

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

We present a 78-year-old male with hormone-refractory prostate cancer (HRPC), who obtained complete long term regression of prostate specific antigen level during zoledronic acid (ZA) therapy. Our case suggests clinical utility of ZA in managing some of HRPC patients.

引用

页码：114 / 115

页数：2

共 7 条

[1] Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?: Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
Collette, L
Burzykowski, T
Carroll, KJ
Newling, D
Morris, T
Schröder, FH
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6139 - 6148
[2] Using anecdotal information in evidence-based health care: Heresy or necessity?
Enkin, MW
Jadad, AR
[J]. ANNALS OF ONCOLOGY, 1998, 9 (09) : 963 - 966
[3] Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone
Kikuno, Nobuyuki
Urakami, Shinji
Nakamura, Shigeru
Shiina, Hiroaki
Igawa, Mikio
[J]. INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (01) : 82 - 84
[4] Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
Petrylak, DP
Tangen, CM
Hussain, MHA
Lara, PN,J
Jones, JA
Taplin, ME
Burch, PA
Berry, D
Moinpour, C
Kohli, M
Benson, MC
Small, EJ
Raghavan, D
Crawford, ED
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) : 1513 - 1520
[5] A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
Saad, F
Gleason, DM
Murray, R
Tchekmedyian, S
Venner, P
Lacombe, L
Chin, JL
Vinholes, JJ
Goas, JA
Chen, B
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (19): : 1458 - 1468
[6] New research findings on zoledronic acid: Survival, pain, and anti-tumour effects
Saad, Fred
[J]. CANCER TREATMENT REVIEWS, 2008, 34 (02) : 183 - 192
[7] Ural AU, INT J HEMATOL

← 1 →